Arvinas, Inc.

NasdaqGS ARVN

Arvinas, Inc. EBT Margin for the Trailing 12 Months (TTM) ending September 30, 2024

Arvinas, Inc. EBT Margin is NA for the Trailing 12 Months (TTM) ending September 30, 2024. EBT Ratio (Earnings Before Tax Ratio) is the fraction of earnings before taxes to total revenue, indicating the company's profitability before the impact of tax expenses.

Arvinas, Inc. EBT Margin for the Trailing 12 Months (TTM) ending September 30, 2023 was -175.31%, a 18.96% change year over year.
Arvinas, Inc. EBT Margin for the Trailing 12 Months (TTM) ending September 30, 2022 was -216.32%, a 72.79% change year over year.
Arvinas, Inc. EBT Margin for the Trailing 12 Months (TTM) ending September 30, 2021 was -794.96%, a -96.88% change year over year.
Arvinas, Inc. EBT Margin for the Trailing 12 Months (TTM) ending September 30, 2020 was -403.77%, a -156.63% change year over year.

Key data

Date	EBT Margin	Net Income Margin	EBITDA Margin	EBIT Margin

NasdaqGS: ARVN

Arvinas, Inc.

CEO	Dr. John G. Houston Ph.D.
IPO Date	Sept. 27, 2018
Location	United States
Headquarters	5 Science Park
Employees	445
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer; and ARV-766 an investigational orally bioavailable PROTAC protein degrader for the treatment of men with mCRPC. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut.

Key trends

Past 5 years